Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.
|Videos|April 29, 2022
Shirley Lee on how practices can increase patient buy-in with their treatment
Author(s)Urology Times staff
“We really need to listen to what people care about and speak to that,” says Shirley Lee, CRNP-FNP, MPH.
Advertisement
In this video, Shirley Lee, CRNP-FNP, discusses ways that busy practices can increase patient buy-in with treatment. Lee is director of a patient navigation program and a nurse practitioner for the Greater Los Angeles Division of Genesis Healthcare Partners and Vice President of Clinical Strategy for Preveta.
Advertisement
Related to this article
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants 510(k) clearance to OpenFlo urinary catheter
2
FDA grants fast track designation to VIR-5500 for mCRPC
3
Variation in PSMA PET Adoption for Prostate Cancer Care
4
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
5